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Abstract 
Objective: The objective of this EBM review is to determine whether the use of intestinal 
helminths is safe and effective in the treatment of allergic rhinitis.  
Study design: Review of three English language, blinded randomized controlled trials from 2009, 
2010, and 2010. 
Data source: Randomized, controlled, blinded trials comparing the use of intestinal helminths 
versus visually matched placebo as a treatment for allergic rhinitis found using PubMed and 
Ovid databases. 
Outcomes measured: Several different systems were used to evaluate the symptoms or 
occurrence of AR. Bager et al.2010 uses symptom scores of AR scale of 0 to 3. Feary et al.2009 
used the Juniper rhinoconjunctivitis quality of life questionnaire. Flohr et al.2010 used the 
International Study of Asthma and Allergies in Childhood (ISAAC). Mean symptom score and 
incidence recorded in daily diaries were used for adverse events.   
Results: Bager et al.2010 reported a mean difference in symptom scores of AR as 0.0 a t-test 
produced a p-value of 0.87 with a 95% CI 0.0(-0.5, 0.4).  Feary et al.2009 reported no difference 
between the treatment and control groups (MD 0.33, 95% CI -0.27 to 0.93).  No serious adverse 
events were reported in Bager et al.2010 or Feary et al.2009. There were several gastrointestinal 
adverse events reported including indigestion, flatus, upper abdominal pain and diarrhea.  
Flohr et al.2010 reported a mean difference of 1.39 between experimental and control groups 
95% CI (0.89-2.15) with a P-value of 0.1.  The relative risk increase of AR was 37% after 
treatment. Absolute risk increase or AR was 1.8%. The number needed to harm (in this case 
cause AR after elimination of helminthic infection) was 56 patients.  
Conclusions: The efficacy of intestinal helminths as a treatment for Allergic rhinitis is 
inconclusive. The P-values comparing the effect of treatment to placebo were not statistically 
significant. The controlled administration of helminths can be considered safe since there have 
been no reports of severe adverse events. Mild Gastrointestinal adverse events have been 
reported. Flohr et al.2010 demonstrates possible protective actions of helminthes but more 
research is warranted to obtain more conclusive data.   
Keywords: Allergic Rhinitis, Helminth   
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INTRODUCITON:  
Allergic rhinitis (AR) is a heterogeneous disorder that despite its high prevalence is often 
undiagnosed. It is characterized by one or more symptoms including sneezing, itching, nasal 
congestion, and rhinorrhea which are precipitated by an allergen. An allergen is defined as an 
environmental substance which may produce a hypersensitivity reaction in the body but may not 
be intrinsically harmful.1  
This paper evaluates three double blind randomized controlled trials. Two of the articles 
evaluate the efficacy and safety of intestinal helminths as treatment for AR. The third trial 
evaluates the prevalence of AR after treatment for intestinal helminths in area endemic with 
intestinal helminths. 
AR is a significant cause of illness and disability. In the United States of America between 
40 and 50 Million people have AR.2 This condition effects between 10 and 30% of adults.2 AR is 
also a common cause of missed school days in children, approximately 40% of children miss 
some school each year due to allergies.2 AR may also play a role in other significant diseases 
such as sinusitis. It is estimated that 55% of people with sinusitis have a history of AR.2 Not only 
does this condition cause a significant amount of illness and missed school it also has a huge 
cost. In 2005 total expenditures to treat AR was $11.2 billion.3 Average expenditures per person 
for those with an AR related expense was $434 for those under age 18, and for those ages 18−64 
was $566.3 This condition also accounts for approximately 12 million doctor-visits per year.4 
Those 12 million doctor-visits congest an already busy health care system and take up precious 
time of the health care workers and adds to the already stressed health care system.  
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There is plenty known about the pathophysiology of AR but the reason why  the immune 
system reacts to these otherwise innocuous particles is still debated. AR occurs when a non-
harmful substance, such as pollen, is entrapped in the nasal mucosa and digested, which releases 
protein allergens. The initial immune reaction occurs when mast cells ladened with IgE for the 
particular allergen comes in contact with the released protein. The mast cells degranulate and 
release inflammatory cytokines and histamine. Eosinophils infiltrate the submucosa and add to 
the edema and damage to the mucosa with the release of major basic protein. The damage from 
the inflammation and edema of the nasal mucosa produce the symptoms of AR.5  
The diagnosis and treatment of AR is very common in the western world. AR is diagnosed 
primarily on typical history of allergic symptoms and physical exam findings including swollen 
nasal membranes, enlarged turbinates, and boggy pale mucosa. A nasal smear may also show 
eosinophilia. But since the symptoms of AR can have multiple causes additional tests may be 
performed. These tests include serological testing for circulating allergen specific IgE and skin 
prick tests using suspected allergens.  
Once the diagnosis is made, the treatment of AR may be initiated. Typical treatments include 
allergen avoidance, pharmacotherapy and immunotherapy. Common pharmaceuticals used for 
AR include antihistamines, topical nasal corticosteroid sprays, decongestants, mast cell 
stabilizers or leukotriene inhibitors. In some severe cases, allergen immunotherapy may be 
attempted. These current treatments for AR are not optimal. Allergen avoidance is usually 
impractical and may cause significant interference in the patient’s life. Pharmacotherapy for AR 
can be a great expense to the patient and in many cases may be ineffective. Topical nasal 
decongestants are associated with Rhinitis Medicamentosa and have the potential for abuse.  
Allergen injection immunotherapy takes between 3-5 years with regular injections administered 
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by a trained health care worker. This may be inconvenient for the patient and very expensive to 
the health care system. The problems with the current treatment options for AR warrant the 
search for a new treatment.   
 A relativity new hypothesis has occurred after several observational studies noted AR, 
asthma and eczema being less common in areas with a high prevalence of helminthic infections. 
It was postulated that helminthic infections may be protective against these immune mediated 
conditions.  Helminths are a type of parasitic worm which infest humans and various animals. 
There are several different categories of helminths including nematodes (round worms), 
trematodes (flukes) and cestodes (tapeworms). Helminths may gain access to their host through a 
few different routes including orally and percutaneously. Once they have gained access to the 
host they would be destroyed by the host immune system. The helminths have evolved with their 
hosts and adapted ways to suppress or avoid the immune response. It is theorized that a side 
result of this modulation of the immune system may dampen the symptoms of AR. Due to this 
theory the use of low burden helminthic infections has been suggested as a treatment for AR.   
OBJECTIVE: 
The objective of this selective EBM review is to determine whether the use of intestinal 
helminths is safe and effective in the treatment of allergic rhinitis. 
METHODS: 
 Criteria for articles to be included in this EBM review include randomized controlled 
trials with participants which suffer from AR or have a current Intestinal helminth infection. The 
interventions included in the search were the administration of any helminth species 
administered in any dose, by any route (oral or percutaneous), for any duration of exposure, and 
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at any developmental stage of the organism. The comparisons used in all three RCTs were 
visually matched placebos.  
Information utilized in this review was found using the PubMed and Ovid databases.  
Inclusion criteria included randomized controlled trials limited to the English language and 
published in peer-reviewed journals.  The key words used in searches were: “intestinal 
helminths” and “allergic rhinitis”. Research was conducted by the author.  Articles were selected 
based on relevance to the clinical question and on the importance of outcomes to the patient 
(POEMs).  The inclusion criteria includes that the studies were randomized, controlled, 
prospective, and included patient oriented outcomes (POEMs).  Exclusion criteria included trials 
which combined analysis of AR and asthma or focused on disease oriented outcomes (DOEs).  
Ultimately, three studies were found and analyzed.  They included: 1) a randomized, controlled, 
double blind trial comparing the resolution of symptoms of AR after administration of 8 doses of 
2500 live T. suis ova with a 21 day interval, 2) a randomized placebo controlled feasibility study 
measuring the resolution of AR symptoms after cutaneous administration of 10 Necator 
americanus, and 3) a randomized, placebo controlled double blind trial of Vietnamese school 
children located in an area endemic for intestinal helminth infections measuring the occurrence 
of AR symptoms after administration of mebendazole 500mg at 0,3,6 and 9 months to eradicate 
helminth infections.  A summary of the statistics used include relative risk increase (RRI), 
absolute risk increase (ARI), number needed to harm (NNH), and p-values. 
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Table 1: Demographics of included studies  
   Study  Study Type N Age 
(yrs.) 
Inclusion criteria Exclusion criteria  W/D Interventions 
Bager 
2010 
Randomized 
double blind 
controlled 
clinical trial  
100 18-
65 
 
Symptoms of grass 
pollen allergy the 
last 2 seasons 
Men or women not 
of childbearing 
potential, scoring 
symptoms >50mm 
on a 100 mm 
visual analogue 
scale during 
previous seasons  
Significant 
asthma, use of 
systemic steroids 
in last 2 months, 
history of severe 
disease, anti-
helminth 
treatment in last 2 
weeks  
4 8 doses of 
2500 live T. 
suis ova with 
a 21 day 
interval 
Feary 
2009 
Randomized 
placebo 
controlled 
feasibility 
study 
30 >18 Current symptoms 
of allergic 
rhinoconjunctivitis 
Diagnosis of 
asthma, other 
significant 
medical disorders, 
pregnant or 
unwilling to use 
contraceptives for 
duration of study   
3 Cutaneous 
administration 
of 10 Necator 
americanus  
 
 
  
Flohr 
2010  
Randomized 
placebo 
controlled 
double blinded 
trial  
1,566 6-12 Vietnamese school 
children grades 1-8 
located in four 
communities in the 
Khanh Son district 
in Vietnam which 
is endemic for 
intestinal 
helminths 
infections    
Not completing 
the baseline 
survey or 
providing a stool 
sample after the 
baseline survey  
79 oral dose of 
mebendazole 
500mg at 
0,3,6,and 9 
months 
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MEASURED OUTCOMES: 
The measured outcomes included were; a change in mean daily total symptom score for 
runny, itchy, sneezing nose; the occurrence of adverse events such as diarrhea, flatulence, and 
upper abdominal pain; and the incidence of rhinitis since the start of treatment with mebendazole 
500mg.  
RESULTS: 
 The data collected from the three studies was presented in either dichotomous or 
continuous or both forms. In the Bager et al.2010 study the efficacy of the treatment with 8 doses 
of 2500 live T. suis ova with a 21 day interval was measured using a daily mean symptom score 
of AR symptoms. The scale used was from 0 to 3, where 0 is no symptoms, 1 is mild symptoms, 
2 is moderate symptoms, and 3 is severe symptoms. The symptoms rated were itchy nose, runny 
nose, sneezing, blocked nose, red/itchy eyes, and watery eyes. They reported no difference 
between the groups. The mean difference was 0.0 a t-test was preformed which produced a p-
value of 0.87 with a 95% CI 0.0(-0.5, 0.4) 
Table 2: Efficacy of T. suis ova in comparison to placebo measured in mean daily symptom 
score  
 TSO Mean 
(SD) 
Placebo Mean 
(SD) 
Difference in 
mean  
P-value 95% CI 
Mean daily 
symptom 
score  
1.4(1.2) 1.4(1.1) 0.0 0.87 (-0.5,0.4) 
 
In Feary et al.2009 the efficacy of cutaneous administration of 10 Necator americanus was 
determined using the Juniper rhinoconjunctivitis quality of life questionnaire (RQLQ) over 12 
weeks. There was no statistically significant difference between the groups (mean difference 
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0.33, P=0.31 95% CI -0.27 to 0.93). The data was adjusted for smoking status and produced an 
adjusted mean difference of 0.26 a 95% CI of -0.45,0.97, and a p-value of 0.46. 
Table 3: Efficacy of N. americanus in comparison to placebo measured with Juniper RQLQ 
score 
 Hookworm 
mean (SD) 
n=13 
Placebo 
mean (SD) 
n=14  
Mean 
difference 
(95% CI) 
P-value Adjusted* 
mean  
difference 
(95% CI) 
P-value  
JuniperRQLQ 
score (log 
area under the 
curve) 
6.01 (0.82) 5.68(0.85) 0.33 
 (-0.33,1.00) 
P= 0.31 0.26 
(-0.45,0.97) 
P=0.46 
*adjusted for smoking status 
 Adverse events were also measured in Bager et al.2010 and Feary et al.2009. There were 
no adverse events requiring hospitalization in Feary et al.2009. Bager et al.2010 reported any 
adverse event and hospitalization due to gastrointestinal events. There was no significant 
difference in either group. Bager et al.2010 reported a greater likelihood of any of the adverse 
event in the subjects receiving helminths. NNH was calculated for the adverse events reported in 
the article and demonstrated the NNH for diarrhea as 7, the NNH for upper abdominal pain and 
flatulence as 4.  
Table 4: Adverse events oral administration of 2500 T. suis ova  
Adverse event  RRI ARI NNH 
Diarrhea 0.46 0.15 7 
Upper abdominal pain  8.25 0.33 4 
Flatulence  1.5 0.26 4 
 
Feary et al.2009 also measured the occurrence of adverse events using a mean daily score 
(scale 1-10) over a total 12 week period. They calculated statistical significance of adverse 
events using the Mann-Whitney U-test. Indigestion was the only statistically significant adverse 
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event which had a mean difference in medians of 0.11 and a calculated P-value of 0.2. Other 
adverse events were reported but were not statistically significant.  
Table 5: Adverse events reported with administration of N. americanous 
                                       Mean daily score (scale 1-10)  over total 12 week period  
                                                                Median (range)                         
symptoms Hookworm 
group 
Placebo group  Difference in 
medians 
P-value 
Diarrhea 0.12 (0-3.37) 0.11 (0-3.88) 0.01 0.59 
Abdominal pain 0.24 (0-3.81) 0.02 (0-3.00) 0.22 0.06 
Flatulence  0.28 (0-1.76) 0.13 (0-2.62) 0.15 0.36 
Indigestion  0.11 (0-2.39) 0 (0-0.87) 0.11 0.02 
 
In Flohr et al.2010 the intervention was the administration of mebendazole 500mg at 0, 3, 
6 and 9 months to eradicate current helminth infections. They then had the parents of the 
Vietnamese school children answer questions from the International Study of Asthma and 
Allergies in Childhood (ISAAC) Phase Two questionnaires translated into Vietnamese. The 
parents answered the question if their child has experienced rhinitis since the start of treatment. 
6.7% of those in the anti-helminthic treatment reported rhinitis while only 4.9% of placebo group 
reported the finding. This produced a mean difference of 1.39 with a 95% CI (0.89-2.15) and a 
P-value of 0.1.  Using this information it was calculated that the relative risk increase of AR was 
37% after treatment. Absolute risk increase or AR was 1.8%. The number needed to harm (in 
this case cause AR after elimination of helminthic infection) was 56 patients.  
DISCUSSION: 
 Bager et al.2010 reported no statistically significant difference in the mean daily 
symptom score between placebo and intervention, which signifies no therapeutic effect on 
rhinitis. . The efficacy of this treatment had a P value of .87 meaning the evidence cannot 
disprove that the results were not due to chance. Additionally for every four patients taking the 
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intervention one additional would also experience GI adverse events. There were several limiting 
factors to this experiment.  The experiment was only done over one grass pollen season and 
compared selected patients based on their scoring of symptoms over the last 2 grass pollen 
seasons. Grass pollen severity can vary with differences in weather from season to season so 
some patients that had grass pollen allergy the last 2 years may not have the same severity of 
symptoms in the year of the trial lowering their average daily score.   
 Feary et al.2009 shows that there is no significant benefit to administering intestinal 
helminths in the treatment of allergic rhinitis. The P-values was listed as 0.46 which indicates 
that this data could have either been random or as an effect of treatment. The adverse effects had 
a range of p values. Indigestion was the only symptom which was statistically significant with a 
P-value of 0.02. The article discusses egg count in the experimental group’s stool, which 
demonstrated only 9 of the 13 in the experimental group had confirmed helminth infections. The 
remaining 4 had a rise in eosinophil count which was suggestive of established adult infestation 
of the bowel but not definite. It is possible that those 4 unconfirmed infections could have 
skewed their outcomes of the trial.  
In Flohr et al.2010  the results of the clinical trial even though not statistically significant 
demonstrate that for every 56 patients treated with anthelminthic treatment 1 more would 
experience symptoms of rhinitis. This demonstrates that there is limited protection provided from 
rhinitis by intestinal helminths. There are several factors that might have affected the outcome of 
the research including parents administering supplemental anthelminthic treatment and not 
honestly reporting its use. The parents also filled out the questionnaire which may have skewed 
the data since they were not the subjects of the experiment and they have missed the symptoms 
of AR in the children.  
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CONCLUSION:    
 From the research preformed and obtained results, there is insufficient evidence to 
support the use of intestinal helminths as an effective treatment of AR. The controlled 
administration of helminths does appear to be safe with reports of no severe adverse events. 
There does appear to be a moderate amount of GI adverse events most significantly indigestion. 
According to Flohr et al.2010 there does appear to be a slight protective element provided by the 
helminths against AR, even thou not statistically significant, but further research with stricter 
guidelines and reporting would be needed for a more definitive answer. More preclinical 
research is required with specific helminth therapy including specific dosing, administration 
technique, and reporting of symptoms before a large scale clinical trial should be undertaken. 
The results of the preclinical trials would need to demonstrate a more statistically significant 
efficacy for the larger clinical trial to be initiated. 
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